论文部分内容阅读
目的:探讨左西孟旦联合中药治疗扩张型心肌病伴心力衰竭临床效果。方法:研究对象选取医院2013年2月—2016年2月收治扩张型心肌病伴心力衰竭患者共130例,以随机抽签法分为对照组(65例)和治疗组(65例),在常规对症干预基础上分别给予左西孟旦单用和与中药联用治疗;比较两组患者近期疗效,治疗前后中医证候积分,超声心动图指标水平,6MWT,MLHFQ评分,TGF-β1及BNP水平等。结果:治疗组患者临床疗效显著优于对照组(P<0.05);治疗组患者治疗后中医证候积分和超声心动图指标水平均显著优于对照组、治疗前(P<0.05);治疗组患者治疗后6MWT和MLHFQ评分均显著优于对照组、治疗前(P<0.05);治疗组患者治疗后TGF-β1和BNP水平均显著低于对照组、治疗前(P<0.05)。结论:左西孟旦联合中药治疗扩张型心肌病伴心力衰竭可有效缓解症状体征,提高心脏功能和运动耐力,改善生活质量,并有助于下调TGF-β1和BNP水平。
Objective: To investigate the clinical effect of levosimendan combined with traditional Chinese medicine in treating dilated cardiomyopathy with heart failure. Methods: A total of 130 patients with dilated cardiomyopathy and heart failure admitted to the hospital from February 2013 to February 2016 were randomly divided into control group (65 cases) and treatment group (65 cases) Symptomatic intervention was given on the basis of levosimendan alone and combined with traditional Chinese medicine treatment; comparison of two groups of patients with short-term efficacy, TCM Syndrome points before and after treatment, echocardiographic parameters, 6MWT, MLHFQ score, TGF-β1 and BNP levels Wait. Results: The clinical efficacy of the treatment group was significantly better than that of the control group (P <0.05). The scores of TCM syndromes and echocardiography in the treatment group were significantly better than those in the control group before treatment (P <0.05) The levels of 6MWT and MLHFQ in patients after treatment were significantly better than those in the control group before treatment (P <0.05). The levels of TGF-β1 and BNP in the treatment group were significantly lower than those in the control group before treatment (P <0.05). Conclusion: Levosimendan combined with traditional Chinese medicine treatment of dilated cardiomyopathy with heart failure can effectively alleviate the symptoms and signs, improve cardiac function and exercise tolerance, improve quality of life, and help to down-regulate TGF-β1 and BNP levels.